These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 36085259)

  • 21. Control of Intestinal Inflammation, Colitis-Associated Tumorigenesis, and Macrophage Polarization by Fibrinogen-Like Protein 2.
    Zhu Y; Zhou J; Feng Y; Chen L; Zhang L; Yang F; Zha H; Wang X; Han X; Shu C; Wan YY; Li QJ; Guo B; Zhu B
    Front Immunol; 2018; 9():87. PubMed ID: 29441068
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fibrinogen-like protein 2 contributes to normal murine cardiomyocyte maturation and heart development.
    Fan C; Chen H; Liu K; Wang Z
    Exp Physiol; 2021 Jul; 106(7):1559-1571. PubMed ID: 33998085
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overexpression of Fibrinogen-Like Protein 2 Promotes Tolerance in a Fully Mismatched Murine Model of Heart Transplantation.
    Bartczak A; Chruscinski A; Mendicino M; Liu H; Zhang J; He W; Amir AZ; Nguyen A; Khattar R; Sadozai H; Lobe CG; Adeyi O; Phillips MJ; Zhang L; Gorczynski RM; Grant D; Levy GA
    Am J Transplant; 2016 Jun; 16(6):1739-50. PubMed ID: 26718313
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fibrinogen-like protein 2: a potential molecular target for glioblastoma treatment.
    Patel R; Traylor JI; Latha K; Heimberger AB; Li S; Rao G
    Expert Opin Ther Targets; 2019 Aug; 23(8):647-649. PubMed ID: 31167575
    [No Abstract]   [Full Text] [Related]  

  • 25. Role of fibrinogen-like protein 2 prothrombinase/fibroleukin in experimental and human allograft rejection.
    Ning Q; Sun Y; Han M; Zhang L; Zhu C; Zhang W; Guo H; Li J; Yan W; Gong F; Chen Z; He W; Koscik C; Smith R; Gorczynski R; Levy G; Luo X
    J Immunol; 2005 Jun; 174(11):7403-11. PubMed ID: 15905589
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overexpression of fibrinogen-like protein 2 induces epithelial-to-mesenchymal transition and promotes tumor progression in colorectal carcinoma.
    Qin WZ; Li QL; Chen WF; Xu MD; Zhang YQ; Zhong YS; Ma LL; Hu JW; Cai MY; He MJ; Yao LQ; Zhou PH
    Med Oncol; 2014 Sep; 31(9):181. PubMed ID: 25129313
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FGL1 and FGL2: emerging regulators of liver health and disease.
    Chen J; Wu L; Li Y
    Biomark Res; 2024 May; 12(1):53. PubMed ID: 38816776
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling.
    Cockle JV; Rajani K; Zaidi S; Kottke T; Thompson J; Diaz RM; Shim K; Peterson T; Parney IF; Short S; Selby P; Ilett E; Melcher A; Vile R
    Neuro Oncol; 2016 Apr; 18(4):518-27. PubMed ID: 26409567
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adenovirus-mediated artificial miRNA targetting fibrinogen-like protein 2 attenuates the severity of acute pancreatitis in mice.
    Ye X; Ding J; Chen Y; Dong J
    Biosci Rep; 2017 Dec; 37(6):. PubMed ID: 29054965
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of Fibrinogen-like proteins in Cancer.
    Yu J; Li J; Shen J; Du F; Wu X; Li M; Chen Y; Cho CH; Li X; Xiao Z; Zhao Y
    Int J Biol Sci; 2021; 17(4):1079-1087. PubMed ID: 33867830
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies.
    Nishikawa H; Koyama S
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34330764
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The FGL2 prothrombinase contributes to the pathological process of experimental pulmonary hypertension.
    Fan C; Wang J; Mao C; Li W; Liu K; Wang Z
    J Appl Physiol (1985); 2019 Dec; 127(6):1677-1687. PubMed ID: 31580221
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fibrinogen-like protein 2 in gastrointestinal stromal tumour.
    Pulkka OP; Viisanen L; Tynninen O; Laaksonen M; Reichardt P; Reichardt A; Eriksson M; Hall KS; Wardelmann E; Nilsson B; Sihto H; Joensuu H
    J Cell Mol Med; 2022 Feb; 26(4):1083-1094. PubMed ID: 35029030
    [TBL] [Abstract][Full Text] [Related]  

  • 34. T-cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer.
    Fathi M; Pustokhina I; Kuznetsov SV; Khayrullin M; Hojjat-Farsangi M; Karpisheh V; Jalili A; Jadidi-Niaragh F
    IUBMB Life; 2021 May; 73(5):726-738. PubMed ID: 33686787
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Deciphering the role of QPCTL in glioma progression and cancer immunotherapy.
    Liu Y; Lu S; Sun Y; Wang F; Yu S; Chen X; Wu LL; Yang H; Shi Y; Zhao K
    Front Immunol; 2023; 14():1166377. PubMed ID: 37063864
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intrauterine inflammation induced white matter injury protection by fibrinogen-like protein 2 deficiency in perinatal mice.
    Zhan D; Zhang C; Long W; Wei L; Jin S; Du C; Li Z; Guo S; Huang L; Ning Q; Luo X
    Pediatr Res; 2021 May; 89(7):1706-1714. PubMed ID: 33075801
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Two fibrinogen-like proteins, FGL1 and FGL2 are disulfide-linked subunits of oligomers that specifically bind nonviable spermatozoa.
    Nagdas SK; Winfrey VP; Olson GE
    Int J Biochem Cell Biol; 2016 Nov; 80():163-172. PubMed ID: 27732889
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Soluble Fgl2 restricts autoimmune hepatitis progression via suppressing Tc17 and conventional CD8+ T cell function.
    Ai G; Yan W; Yu H; Xiao F; Xi D; Ma K; Huang J; Luo X; Wan X; Ning Q
    J Gene Med; 2018 Jul; 20(7-8):e3023. PubMed ID: 29756667
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The novel CD4+CD25+ regulatory T cell effector molecule fibrinogen-like protein 2 contributes to the outcome of murine fulminant viral hepatitis.
    Shalev I; Wong KM; Foerster K; Zhu Y; Chan C; Maknojia A; Zhang J; Ma XZ; Yang XC; Gao JF; Liu H; Selzner N; Clark DA; Adeyi O; Phillips MJ; Gorczynski RR; Grant D; McGilvray I; Levy G
    Hepatology; 2009 Feb; 49(2):387-97. PubMed ID: 19085958
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-grade glioma associated immunosuppression does not prevent immune responses induced by therapeutic vaccines in combination with T
    Löhr M; Freitag B; Technau A; Krauss J; Monoranu CM; Rachor J; Lutz MB; Hagemann C; Kessler AF; Linsenmann T; Wölfl M; Ernestus RI; Engelhardt S; Gelbrich G; Schlegel PG; Eyrich M
    Cancer Immunol Immunother; 2018 Oct; 67(10):1545-1558. PubMed ID: 30054667
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.